COVID-19 Trial to Combat Delta Variant

UT Health Science Center at Houston, Baylor College of Medicine and Johns Hopkins University are enrolling for two new Covid-19 treatment and prevention studies in the Houston metro area. If you have recently been diagnosed with COVID-19, you may be eligible, and participants will be compensated up to $575.

This is the first U.S. multi-center, double-blind, randomized clinical trial to assess the effectiveness of convalescent blood plasma as an outpatient therapy. Antibodies are one of the best options being tested for treatment and prevention.

The trial organizers seek to enrol anyone who has tested positive for COVID-19. This study is funded by the US government and has not received any funding from a pharmaceutical company.

Participants must be over age 18 and have tested for Covid-19 no more than 5 days ago, received a positive diagnosis, have ongoing symptoms, but have not been hospitalized,

Those who are newly diagnosed and have symptoms, should contact Johns Hopkins at 888-506-1199 or to learn more about eligibility, participation and compensation. Trials are being conducted on-site at UT Health Science Center in and at Baylor College of Medicine in Houston.

Do I qualify?: Call 888-506-1199, or visit to take the enrolment questionnaire. This study is entirely voluntary, and participants will be compensated.